Meizhou

Researchers are evaluating patritumab deruxtecan MK-1022 as a treatment for advanced gastrointestinal cancers, including unresectable or metastatic colorectal cancer, biliary tract cancer, hepatocellular carcinoma, and gastroesophageal cancer. This study aims to learn about the safety and tolerability of patritumab deruxtecan and to see how many participants experience their cancer shrinking or disappearing in response to the treatment. Participants receive patritumab deruxtecan through an intravenous infusion on the first day of every 21-day cycle. Treatment continues until the cancer progresses, side effects become intolerable, or the investigator decides to stop. The study includes a dose-escalation phase to evaluate safety and further phases to assess treatment efficacy over time. During the trial, participants will be monitored for dose-limiting toxicities, adverse events, and reasons for discontinuing treatment. Researchers will measure the objective response rate, duration of response, progression-free survival, overall survival, and drug concentration levels in the blood. The study may last up to approximately 44 months, with ongoing assessments to understand the treatments effects and safety.